InduPro is delighted to announce the publication of a new review article featured on the cover of Cell Chemical Biology titled, “Therapeutic potential of cis-targeting bispecific antibodies”, which serves to highlight our position at the forefront of developing next generation proximity based cis-bispecific targeting modalities. In this review, InduPro Scientific Founders and Leadersip- Rob Oslund, Pamela Holland, Scott Lesley and Niyi Fadeyi- discuss the progress and impact of cis-bispecific antibodies (cis-bsAbs) in the clinic, their wide-ranging clinical applications, and untangle the intricacies of improving bsAb discovery and development. They further highlight emerging therapeutic strategies to develop next generation cis-bsAbs that include our novel proximity based co-targeting approach leveraging InduPro's Tumor Associated Proximity Antigens (TAPAs) for selective tumor targeting. https://lnkd.in/ee-ZWb9A #cis-bispecific-targeting #protein-proximity #proximitybydesign #ProXiMATE #induprotx
Über uns
InduPro is bringing life-changing therapies to patients through novel cell-surface platform technologies. We are defining and manipulating protein interactions beyond natural signaling paradigms. InduPro platforms, integrate inherent protein proximity at the cell surface with the ability to manipulate protein pairings via induced protein proximity to create novel signaling pathways and logic gates.
- Website
-
https://www.induprotx.com/
External link for InduPro
- Industrie
- Biotechnology
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Seattle, WA
- Typ
- In Privatbesitz
- Gegründet
- 2022
- Spezialitäten
- biotechnology
Standorte
-
Primäre
Seattle, WA 98101, US
-
Cambridge, MA, US
Employees at InduPro
Aktualisierungen
-
InduPro is in the news! We are grateful to Ryan Cross from Endpoints News for this Exclusive interview with our CEO Prakash Raman and President & CSO Scott Lesley on the founding of the company, as well as the origins of our MInt technology. MInt one of the 3 central components of our powerful ProXiMATE platform, a truly differentiated and industrialized technology workstream that drives the discovery of both inherent and induced proximity biology-based novel drug targets.
-
We’re thrilled to announce our $85 Million Series A financing and the appointment of Prakash Raman, Ph.D., as CEO to advance next-generation, proximity-based protein therapeutics for the treatment of cancer and autoimmune diseases. Learn more here: https://lnkd.in/gNhhNpEq #biotech #immunooncology #autoimmune #ADC #bispecifics
-
-
Earlier today, our President and CSO Scott Lesley presented at Biotech Showcase on Indupro's exciting and differentiated take on proximal biology, and how we are using our ProXiMATE platform to drive novel therapeutics. #jpm2024 #BiotechShowcase2024
-
-
In addition to Biotech Showcase, InduPro will also be taking 1:1 meetings at BIO. If you are also attending and want to learn more about our cutting edge approach to induced and inherent proximity biology via our proprietary ProXiMATE platform, reach out to schedule a meeting! #BIOJPM2024
Register Now
share.bio.org
-
InduPro is proud to have been selected to present at #BiotechShowcase! Join us in San Francisco on Monday, January 8 at 2:30PM in the Franciscan Ballroom C to attend our presentation. Register now to meet one-to-one: biotechshowcase.com.
-